Jun 25, 2021
- Comparative data presented at the American Diabetes Association 81st Scientific Sessions show Abbott's diabetes technology delivers the same reductions of HbA1c and acute complications(1,2) as the competitor systems while reaching a much wider, more diverse population
- Priced at a third of the cost of other available continuous glucose monitoring systems(3), data suggests increasing use of FreeStyle Libre system could save Medicaid millions annually(4) by reducing costly complications
- The groundbreaking FreeStyle Libre portfolio has been extensively studied with real-world data from more than 1 million users(5) and clinical evidence, showing it helps people with diabetes significantly improve their health and quality of life(6)